Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multicenter, phase III trial

Supportive Care in Cancer

Volumn 19, Issue 8, 2011, Pages 1217-1225

  Celio, Luigi ^a   Frustaci, Sergio ^b   Denaro, Angela ^a   Buonadonna, Angela ^b   Ardizzoia, Antonio ^c   Piazza, Elena ^d   Fabi, Alessandra ^e   Capobianco, Alba Maria ^f   Isa, Luciano ^g   Cavanna, Luigi ^h   Bertolini, Alessandro ⁱ   Bichisao, Ettore ^j   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f Centro Riferimento Oncologico della Basilicata   (Italy)

^g Ospedale Serbelloni   (Italy)

^h GUGLIELMO DA SALICETO HOSPITAL   (Italy)

ⁱ Ospedale di Sondrio   (Italy)

^j ITMO Operative Office   (Italy)

more..

Author keywords

Dexamethasone; Moderately emetogenic chemotherapy; Nausea; Palonosetron; Serotonin antagonists; Vomiting

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IRINOTECAN; METOCLOPRAMIDE; OXALIPLATIN; PALONOSETRON;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BOLUS INJECTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DEXAMETHASONE; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; QUINUCLIDINES; RISK ASSESSMENT; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 80051600512     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0941-7     Document Type: Article

References (22)

1. R Sharma P Tobin SJ Clarke 2005 Management of chemotherapy-induced nausea, vomiting, oral mucositis, diarrhoea Lancet Oncol 6 93 102 10.1016/S1470-2045(05)01735-3 15683818 10.1016/S1470-2045(05)01735-3 1:CAS:528:DC%2BD2MXosFyntg%3D%3D (Pubitemid 40197703)
2. SM Grunberg 2007 Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis Ann Oncol 18 233 240 17108149 10.1093/annonc/mdl347 1:STN:280: DC%2BD2s%2FotleltQ%3D%3D (Pubitemid 46323087)
3. PJ Hesketh 2008 Chemotherapy-induced nausea and vomiting N Engl J Med 358 2482 2494 18525044 10.1056/NEJMra0706547 1:CAS:528:DC%2BD1cXmvFKltL0%3D (Pubitemid 351793021)
4. PJ Hesketh MG Kris SM Grunberg, et al. 1997 Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103 109 8996130 1:STN:280:DyaK2s7kvFehsA%3D%3D (Pubitemid 27020563)
5. F Roila PJ Hesketh J Herrstedt, et al. 2006 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann Oncol 17 20 28 10.1093/annonc/mdj078 16314401 10.1093/annonc/mdj936 1:STN:280:DC%2BD28%2FkvVKmtQ%3D%3D (Pubitemid 43033835)
6. A Naeim SM Dy KA Lorenz H Sanati A Walling SM Asch 2008 Evidence-based recommendations for cancer nausea and vomiting J Clin Oncol 26 3903 3910 10.1200/JCO.2007.15.9533 18688059 10.1200/JCO.2007.15.9533
7. JP Ioannidis PJ Hesketh J Lau 2000 Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence J Clin Oncol 18 3409 3422 11013282 1:CAS:528: DC%2BD3cXnslWjsr0%3D
8. J Vardy KS Chiew J Galica GR Pond IF Tannock 2006 Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy Br J Cancer 94 1011 1015 10.1038/sj.bjc. 6603048 16552437 10.1038/sj.bjc.6603048 1:CAS:528:DC%2BD28XjtFGqt7c%3D
9. O Geling H-G Eichler 2005 Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications J Clin Oncol 23 1289 1294 10.1200/JCO.2005.04.022 15718327 10.1200/JCO.2005.04.022 1:CAS:528:DC%2BD2MXitl2gurc%3D (Pubitemid 46202287)
10. MA Siddiqui LJ Scott 2004 Palonosetron Drugs 64 1125 1132 15139789 10.2165/00003495-200464100-00006 1:CAS:528:DC%2BD2cXlsVGisLY%3D (Pubitemid 38736896)
11. R Gralla M Lichinitser S Van Der Vegt, et al. 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570 1577 10.1093/annonc/mdg417 14504060 10.1093/annonc/mdg417 1:STN:280: DC%2BD3svktlKitQ%3D%3D (Pubitemid 37304615)
12. P Eisenberg J Figueroa-Vadillo R Zamora, et al. 2003 Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2473 2482 10.1002/cncr.1187 14635083 10.1002/cncr.11817 1:CAS:528:DC%2BD3sXpvFOrt70%3D (Pubitemid 37466663)
13. Rubenstein EB, Gralla RJ, Eisenberg P, et al (2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Combined results of two Phase III trials. Proc Am Soc Clin Oncol 22:729. Available at: http://www.asco.org/ASCO/Abstracts. Accessed 19 February 2009
14. F Roila D Warr RA Clark-Snow, et al. 2005 Delayed emesis: moderately emetogenic chemotherapy Support Care Cancer 13 104 108 10.1007/s00520-004-0700-8 15549426 10.1007/s00520-004-0700-8 (Pubitemid 40558165)
15. J Hajdenberg T Grote L Yee R Arevalo-Araujo LA Latimer 2006 Infusion of palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting J Support Oncol 4 467 471 17080735 1:CAS:528:DC%2BD28Xht1Wjt7fE (Pubitemid 44698155)
16. C Rojas M Stathis AG Thomas, et al. 2008 Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor Anesth Analg 107 469 478 10.1213/ane.06013e318172fa74 18633025 10.1213/ane.0b013e318172fa74 1:CAS:528:DC%2BD1cXoslGktrc%3D
17. DG Warr PJ Hesketh RJ Gralla, et al. 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830 10.1200/JCO.2005.09.050 15837996 10.1200/JCO.2005.09.050 1:CAS:528:DC%2BD2MXktleqt74%3D (Pubitemid 46179473)
18. M Aapro A Fabi F Nolè, et al. 2010 Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy Ann Oncol 21 1083 1088 10.1093/annonc/mdp584 20080830 10.1093/annonc/mdp584 1:STN:280:DC%2BC3c3pt1Sguw%3D%3D
19. MASCC/ESMO Antiemetic Guidelines. Available at: http://data.memberclicks. com/site/mascc/MASCC-Guidelines-English-2010.pdf. Accessed 31 May 2010
20. T Grote J Hajdenberg A Cartmell S Ferguson A Ginkel V Charu 2006 Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant J Support Oncol 4 403 408 17004515 1:CAS:528:DC%2BD28XhtVKntr7L (Pubitemid 44541016)
21. SM Grunberg M Dugan H Muss, et al. 2009 Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy Support Care Cancer 17 589 594 10.1007/s00520-008-0535-9 19037667 10.1007/s00520-008-0535-9
22. F Giuliani G Cilenti I Nugnes, et al. 2008 Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: A phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM) Eur J Cancer Suppl 6 102 106 10.1016/j.ejcsup.2008.06.018 10.1016/j.ejcsup.2008.06.018